Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Sydney, Oct 24, 2006 AEST (ABN Newswire) - Life Therapeutics (ASX: LFE)(PNK: LFEFY) has signed a new two year contract to produce hyperimmune plasma for a major fractionator. The value of the contract ranges from a minimum of A$4M up to A$12M per year for two years.
"This contract signals our further shift to producing the high-margin, hyperimmune plasma, which will further enhance our product mix," said Dr. Hari Nair, CEO and President of Life Therapeutics. "These types of high-margin products are what our company excels in producing and what our entire production system is geared to accomplish."
As previously advised, Life Therapeutics recently installed a new donor computer system company-wide to increase processing and aid production of hyperimmune and normal source plasma. This will further reduce the cost of product management and improve the order fulfilment process.
